Efficacy of dupilumab in eosinophilic dermatosis of haematologic malignancy (EDHM) needs to be confirmed

we read with interest the case report recently published by maglie et al. of a rapid improvement after only 1 injection of treatment with the fully human anti-interleukin-4 receptor α monoclonal antibody dupilumab in a patient with recalcitrant eosinophilic dermatosis of haematologic malignancy (EDHM). This result appears very promising and consistent with a similar observation previously reported. This is all the more important as EDHM remains very difficult to manage.